Last updated: April 24, 2026
Who supplies DIPRIVAN to the market?
DIPRIVAN is a branded formulation of propofol (2,6-diisopropylphenol) in an emulsion. In practice, DIPRIVAN supply is carried through two layers:
- Brand holder / marketing authorization holder (MAH) who contracts drug substance and fill-finish to supply finished DIPRIVAN products.
- Specialty suppliers for the drug substance (propofol) and the drug-product system (emulsion excipients, sterile fill-finish, and packaging).
Propofol is not a bulk generic chemical commodity; it is a specialized, regulated input requiring controlled impurity profiles and validated manufacturing.
Which companies supply the drug substance used in DIPRIVAN?
The supply of propofol drug substance for major injectable brands is dominated by established specialty API producers with validated routes and impurity control for parenteral use. For DIPRIVAN specifically, the supplier list is typically protected by commercial terms, but the underlying propofol API production base in global markets is concentrated among a limited set of qualified manufacturers supplying regulated markets.
Which companies support the DIPRIVAN drug-product manufacturing (emulsion + sterile fill-finish)?
DIPRIVAN is produced as a sterile emulsion injectable. That means the critical supplier categories are:
- Emulsion excipients and formulation inputs (for parenteral use)
- Sterile manufacturing sites (aseptic processing)
- Primary packaging components (sterile vial system, stoppers, seals)
- Packaging and carton supply (labeling and traceability)
The drug-product supply chain is therefore typically built around a qualified fill-finish network aligned to the brand’s regulatory strategy.
What procurement inputs matter most for DIPRIVAN (what you buy, not just who makes it)?
DIPRIVAN is a propofol emulsion. Procurement decisions for supply resilience typically target these inputs:
| Input class |
Why it constrains supply |
Typical qualification gate |
| Propofol API |
Impurity profile and parenteral specs |
DMF review, CoA alignment, stability/viral safety dossier |
| Emulsion excipients |
Parenteral-grade sourcing and compatibility |
Raw material specs, extractables/leachables where relevant |
| Sterile fill-finish |
Aseptic capacity is a bottleneck |
Audit status, media fill history, site validation |
| Closure and container system |
Elastomer supply and interchangeability |
Container closure integrity and extractables studies |
| Labeling and serialization |
Market-specific packaging compliance |
Artwork approvals and track-and-trace mapping |
How DIPRIVAN is positioned in the market supply landscape
DIPRIVAN demand concentrates in hospital anesthesia and ICU workflows. Supply risk therefore tracks:
- Aseptic fill-finish capacity
- Propofol API availability
- Container closure availability (vial/stopper systems)
What does the formal regulatory record say about manufacturing?
A complete and accurate “supplier list” for DIPRIVAN requires direct referencing of the drug’s regulatory dossier for each jurisdiction (MAA/NDA listing of manufacturers, sites, and batch release testing), and those listings vary by country, pack strength, and presentation.
For an actionable procurement and counterparty mapping exercise, the correct method is to pull the named manufacturing sites and testing sites from the applicable label and regulatory filings for each territory.
DIPRIVAN supply chain map (actionable framework)
Use this map to identify real counterparties behind each supply lane:
- Finished dose manufacturer(s): sterile fill-finish site(s listed on the product label/regulatory documents for the target territory.
- Release testing site(s): QC laboratories responsible for batch release.
- API manufacturer(s): named in the regulatory dossier (often via DMF references in jurisdictions where allowed).
- Raw excipient manufacturers: generally not always disclosed publicly, but can be inferred from excipient supplier lists in regulatory content where available.
- Packaging component suppliers: closure and carton vendors may not be public by name, but container closure is usually a known configuration used for interchangeability.
Market counterparties: how to treat “suppliers” in procurement
For business planning, count counterparties in tiers:
- Tier 1 (named, on-label / in-file): finished manufacturing site and release site.
- Tier 2 (API and primary emulsion inputs): drug substance and key excipients listed in regulatory documentation.
- Tier 3 (supporting materials): vials, stoppers, overwraps, printed cartons, and serialization components.
Key Takeaways
- DIPRIVAN supply is constrained less by simple “commodity” chemical sourcing and more by parenteral-qualified propofol API, emulsion excipient sourcing, and sterile aseptic fill-finish capacity.
- A true supplier list is jurisdiction- and presentation-specific; the reliable “who supplies DIPRIVAN” answer is the set of named manufacturing and testing sites in the local product dossier/label plus the named propofol API and key input suppliers referenced there.
- For procurement resilience, prioritize supplier tiering: finished dose manufacturer and release testing first, then API and emulsion inputs, then container closure and packaging.
FAQs
-
Is DIPRIVAN supplied by one manufacturer globally?
No. Finished-dose manufacturing and release testing are typically assigned by jurisdiction and site, even when the same brand is used.
-
Who makes the propofol used in DIPRIVAN?
Propofol is supplied by qualified propofol API manufacturers feeding the brand holder’s approved formulation and sterile manufacturing workflow, with named suppliers in regulatory documentation.
-
What is the biggest bottleneck for DIPRIVAN supply?
Aseptic sterile fill-finish capacity and parenteral-qualified propofol API availability.
-
Do container closure components affect DIPRIVAN supply risk?
Yes. Closure and vial systems must meet container closure integrity and compatibility requirements, and they can constrain interchangeability during shortages.
-
How should procurement teams identify the real DIPRIVAN suppliers?
Pull the named manufacturing and release sites and the named API/ingredient references from the target territory’s regulatory/label record, then map those to contracting entities and lead-time constraints.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drug safety and availability information for propofol (DIPRIVAN). https://www.accessdata.fda.gov/
[2] European Medicines Agency. (n.d.). EPAR information for propofol products (DIPRIVAN). https://www.ema.europa.eu/
[3] DailyMed. (n.d.). DIPRIVAN (propofol) injectable emulsion prescribing information. https://dailymed.nlm.nih.gov/
